Cargando…
Systemic Therapy for Invasive Bladder Cancer: The Value Proposition
Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy followed by definitive local treatment should be the treatment of choice for otherwise healthy and robust patients with T2b–T4 invasive bladder cancer.
Autor principal: | Raghavan, Derek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912376/ https://www.ncbi.nlm.nih.gov/pubmed/27125752 http://dx.doi.org/10.1634/theoncologist.2016-0074 |
Ejemplares similares
-
The Conceptualization of Value in the Value Proposition of New Health Technologies : Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies"
por: Buttigieg, Sandra C., et al.
Publicado: (2017) -
A Modest Proposition to align Geriatrics and Long Term Care Medicine
por: Mor, Vincent, et al.
Publicado: (2008) -
Employee Value Proposition for CERN
por: Department, HR
Publicado: (2010) -
CERN Employee Value Proposition
por: Cook, Anna
Publicado: (2021) -
Simple and Efficient Stratification of Invasive Bladder Cancer Patients
por: Zoidakis, Jerome
Publicado: (2016)